Schott Pharma AG KGaASHTPY -42.88%64 3-Year ROIIC % is 4.01 as of Sep. 2025, which is 64% below its 10-year median of 11.13. GuruFocus rates SHTPY with a GF Score™ of 64/100 and a GF Value™ of $7.02. The stock has 2 warning signs investors should review. Among 800 Medical Devices & Instruments companies, Schott Pharma AG KGaA ranks better than 54.37% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Schott Pharma AG KGaA's 3-Year ROIIC % for the quarter that ended in Sep. 2025 was 4.01%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Schott Pharma AG KGaA's 3-Year ROIIC % or its related term are showing as below:
SHTPY's 3-Year ROIIC % is ranked better than 54.37% of 800
companies
in the Medical Devices & Instruments industry
Industry Median: 1.455
vs SHTPY: 4.01
Schott Pharma AG KGaA (OTCPK:SHTPY) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Schott Pharma AG KGaA 3-Year ROIIC % Related Terms
Schott Pharma AG KGaA 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Schott Pharma AG KGaA's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHTPY vs ISRG, BDX, MDLN: 3-Year ROIIC % Comparison
For the Medical Instruments & Supplies subindustry, Schott Pharma AG KGaA's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Schott Pharma AG KGaA 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Schott Pharma AG KGaA's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Schott Pharma AG KGaA's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Schott Pharma AG KGaA (SHTPY) has a 3-Year ROIIC % of 4.01 as of Sep. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Schott Pharma AG KGaA and its competitors. This is 64% below median its historical median of 11.13. Over the past decade, Schott Pharma AG KGaA's 3-Year ROIIC % has ranged from 4.01 to 12.04. According to the industry distribution chart, Schott Pharma AG KGaA ranks #365 out of 800 companies in the Medical Devices & Instruments industry, placing it in the top 45.6%.
Is Schott Pharma AG KGaA's 3-Year ROIIC % too high?
Schott Pharma AG KGaA's current 3-Year ROIIC % of 4.01 is 64% below median its 10-year median of 11.13. Over the past 10 years, this metric has ranged from a low of 4.01 to a high of 12.04. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.46. Schott Pharma AG KGaA's value of 4.01 is 175.6% above this industry median. Based on the distribution chart, Schott Pharma AG KGaA ranks #365 out of 800 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Schott Pharma AG KGaA has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Schott Pharma AG KGaA's 3-Year ROIIC % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Schott Pharma AG KGaA ranks #365 out of 800 companies for 3-Year ROIIC %. This puts Schott Pharma AG KGaA in the upper half of its industry. The industry median 3-Year ROIIC % is 1.46. Schott Pharma AG KGaA's value of 4.01 is 175.6% above this benchmark. Historically, Schott Pharma AG KGaA's own 3-Year ROIIC % has ranged from 4.01 to 12.04 over the past decade. While the company's 10-year median is 11.13 vs. the industry median of 1.46, Schott Pharma AG KGaA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.46, based on 800 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Schott Pharma AG KGaA's current 3-Year ROIIC % of 4.01 is 175.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Schott Pharma AG KGaA and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Schott Pharma AG KGaA's current 3-Year ROIIC % is 4.01, which is 64% below median its own 10-year median of 11.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Schott Pharma AG KGaA stock overvalued right now?
Schott Pharma AG KGaA (SHTPY) has a current 3-Year ROIIC % of 4.01. The stock's GF Value™ is $7.02, compared to a current price of $4.37 — trading 37.7% below its estimated fair value. The current 3-Year ROIIC % is 4.01, which is 64% below median its 10-year median of 11.13 and 175.6% above the Medical Devices & Instruments industry median of 1.46. Schott Pharma AG KGaA's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Schott Pharma AG KGaA (SHTPY), the current 3-Year ROIIC % is 4.01 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Schott Pharma AG KGaA (SHTPY) Overvalued in 2026?
Based on GuruFocus' analysis, Schott Pharma AG KGaA stock appears to be undervalued.
The current stock price of $4.37 is trading 37.7% below its estimated GF Value™ of $7.02.
Key valuation signals for SHTPY:
3-Year ROIIC %: 4.01 (64% below median its 10-year median of 11.13)
GF Value™: $7.02 vs. price of $4.37 (37.7% below fair value)
Industry Position: 175.6% above the Medical Devices & Instruments median (#365 of 800)
No single metric tells the full story. See the SHTPY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Schott Pharma AG & CO KGaA is an international provider of drug containment solutions and delivery systems for injectable drugs for pharma, biotech and life-sciences. Its business operates in two segments: Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of revenue is being generated from the DCS segment, which includes products like vials, cartridges, and ampoules, and provides customers with sterile and non-sterile options in standard and high-end formats for drug storage. Geographically, the company generates revenue from Europe, the Middle East, Africa (EMEA), Asia and the South Pacific, North America, and South America.
64GF Score
Get the complete analysis for SHTPY
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTPY has been successfully added to your 
